Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2000-01-28
2002-06-04
Stucker, Jeffrey (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C424S085200, C530S351000
Reexamination Certificate
active
06399573
ABSTRACT:
FIELD OF INVENTION
This invention relates to newly identified polynucleotides, polypeptides encoded by them and to the use of such polynucleotides and polypeptides, and to their production. More particularly, the polynucleotides and polypeptides of the present invention relate to Interleukin-1 family, hereinafter referred to as IL-1ra beta. The invention also relates to inhibiting or activating the action of such polynucleotides and polypeptides.
BACKGROUND OF THE INVENTION
Interleukin 1 refers to two proteins (IL1&agr; and IL1&bgr;) which play a key role early in the inflammatory response [for a review see C. A. Dinarello, Blood, 87:2095-2147 (1996) and references therein]. Both proteins are made as 31 kDal intracellular precursor proteins which are cleaved upon secretion to yield mature carboxy-terminal 17 kDal fragments which are biologically active. In the case of IL-1&bgr;, this cleavage involves an intracellular cysteine protease, known as ICE, which is required to release the active fragment from the inactive precursor. The precursor of IL-1&agr; is active.
These two proteins act by binding to cell surface receptors found on almost all cell types and triggering a range of responses either alone or in concert with other secreted factors. These range from effects on proliferation (eg of fibroblasts, T cells), apoptosis (eg A375 melanoma cells), cytokine induction (eg of TNF, IL, IL8), receptor activation (eg E-selectin), eicosanoid production (eg PGE2) and the secretion of degradative enzymes (eg collagenase). To achieve this, IL-1 activates transcription factors such as NF-&kgr;B and AP-1, Several of the activities of IL-1 action on target cells are believed to be mediated through activation of kinase cascades that have also been associated with cellular stresses, such as the stress activated MAP kinases JNK/SAPK and p38.
A third member of the IL-1 family was subsequently discovered which acts as a natural antagonist of IL-1&agr; and IL-1&bgr; by binding to the IL-1 receptor but not transducing an intracellular signal or a biological response. The protein was called IL-1ra (for IL-1 receptor antagonist) or IRAP (for IL-1 receptor antagonist protein). At least three alternatively splice forms of IL-1ra exist: one encodes a secreted protein, and the other two encode intracellular proteins. The relative role of the three forms and reason for their different localization is not known. All three proteins, IL-1&agr;, IL-1&bgr; and IL-1ra share approximately 25-30% amino acid identity and a similar three-dimensional structure consisting of twelve &bgr;-strands folded into a &bgr;-barrel, with an internal thrice repeated structural motif.
There are three known IL-1 receptor subunits. The active receptor complex consists of the type I receptor and IL1RAcP (for IL-1 accessory protein). The type I receptor is responsible for binding of the three ligands, and is able to do so in the absence of the IL1RAcP. However signal transduction requires interaction of IL-1&agr; or &bgr; with the IL1RAcP. IL-1ra does not interact with the IL-1RAcP and hence cannot signal. A third receptor subunit, the type II receptor, binds IL-1&agr; and IL-1&bgr; but cannot signal due to its lack of an intracellular domain. Rather it act as a decoy either in its membrane form or an antagonist in a cleaved secreted form, and hence inhibits IL-1 activity. It only weakly binds IL-1ra.
Many studies using IL-1ra, soluble IL-1R, derived from the extracellular domain of the type I IL-1R, antibodies to IL-1&agr; or &bgr; and transgenic knockouts of these genes have shown conclusively that the IL-1s play a key role in a number of pathophysiologies (see C. A. Dinarello, Blood 87:2095-2147 (1996) for a review). For example, IL-1ra has been shown to be effective in animal models of septic shock, rheumatoid arthritis, graft versus host disease, stroke, cardiac ischemia, and is currently in clinical trials for some of these indications. Moreover, IL-1&agr; and &bgr; have shown some potential as hematopoietic stem cell stimulators with potential as radio- and chemoprotectants.
More recently, a more distant member of the IL-1 family was identified. This protein, originally isolated through its ability to induce Interferon gamma in T cells and hence called Interferon gamma inducing factor (IGIF) [H. Okamura et al., Nature 378:88-91 (1995)], was subsequently shown to fold in a similar structure to the IL-1s and share weak amino acid identity [Bazan et al., Nature 379:591 (1996)]. The name IL-1&ggr; was proposed. IGIF appears to play a direct role in the liver damage which occurs during toxic shock and is therefore like the other IL-1s in playing an early role in inflammatory and stressful conditions.
This indicates that these Interleukin-1s have an established, proven history as therapeutic targets. Clearly there is a need for identification and characterization of further members of Interleukin-1 family which can play a role in preventing, ameliorating or correcting dysfunctions or diseases, including, but not limited to, chronic and acute inflammation, septicemia, shock, arthritis, inflammatory bowel disease, graft vs. host disease, autoimmunity, stroke, cardiac ischemia, acute respiratory disease syndrome (ARDS), psoriasis, restenosis, traumatic brain injury, AIDS, cachexia, allergy, parasite infection, allergic rhinitis, allergic asthma, atopic dermatitis, allergic inflammatory diseases, and delayed hypersensitivity.
SUMMARY OF THE INVENTION
In one aspect, the invention relates to IL-1ra beta polypeptides and recombinant materials and methods for their production. Another aspect of the invention relates to methods for using such IL-1ra beta polypeptides and polynucleotides. Such uses include the treatment of chronic and acute inflammation, septicemia, arthritis, inflammatory bowel disease, graft vs. host disease, autoimmunity, stroke, shock, cardiac ischemia, acute respiratory disease syndrome (ARDS), psoriasis, restenosis, traumatic brain injury, AIDS, cachexia, allergy, parasite infection, allergic rhinitis, allergic asthma, atopic dermatitis, allergic inflammatory diseases, and delayed hypersensitivity,, among others. In still another aspect, the invention relates to methods to identify agonists and antagonists using the materials provided by the invention, and treating conditions associated with IL-1ra beta imbalance with the identified compounds. Yet another aspect of the invention relates to diagnostic assays for detecting diseases associated with inappropriate IL-1ra beta activity or levels.
REFERENCES:
patent: 5075222 (1991-12-01), Hannum et al.
patent: 5455330 (1995-10-01), Haskill et al.
patent: 5863769 (1999-01-01), Young
patent: WO9609323 (1996-03-01), None
GenBank Accession No. G10162.
GenBank Accession No. N59092.
GenBank Accession No. T25675.
Gu et al., “Activation of Interferon—? Inducing Factor Mediated by Interleukin-1&bgr; Converting Enzyme”, Science, vol. 275, pp. 206-209 (1997).
Bazan et al., “A newly defined interleukin-1”, Nature, vol. 379, p. 591 (1996).
Okamura et al., “Cloning of a new cytokine that induces IFN-? production by T cells”, Nature, vol. 378, pp. 88-91 (1995).
Haskill et al., “cDNA cloning of an intracellular form of the human interleukin 1 receptor antagonist Associated with epithelium”, Proc. Natl. Acad. Sci., vol. 88, pp. 3681-3685 (1991).
Hannum et al., “Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor”, Nature, vol. 343, pp. 336-340 (1990).
Carter et al., “Purification cloning, expression and biological characterization of an interleukin-1 receptor Antagonist Protein”, Nature, vol. 344, pp. 633-638 (1990).
Eisenberg et al., “Primary Structure and Functional Expression from Complementary DNA of a Human Interleukin-1 Receptor Antagonist”, Nature, vol. 343, pp. 341-346.
Auron et al., “Nucleotide Sequence of Human Monocyte Interleukin-1 Precursor cDNA”, Proc. Natl. Acad. Sci. USA, vol. 81, pp. 7907-7911 (1984).
C. J. March et al., “Cloning sequence and expression of two distinct human interleukin-1 complementary
Han William T.
King William T.
Kinzig Charles M.
Seharaseyon Jegatheesan
SmithKline Beecham Corporation
LandOfFree
Interleukin-1 receptor antagonist beta (IL-1rabeta) does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Interleukin-1 receptor antagonist beta (IL-1rabeta), we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Interleukin-1 receptor antagonist beta (IL-1rabeta) will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2918435